Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofirnoflast in Third Molar Extraction
NCT06241742Phase 2Completed
- Sponsor
- Halia Therapeutics
- Start
- Feb 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute pain and acute inflammation comparing HT-6184 Treatment Arm with Placebo Arm (2 arms). Primary endpoints: Change in serum C-reactive protein levels from pre-dose, Incidence of adverse events and 1 more. Started Feb 2024; status: completed.
02
Drugs
ofirnoflast
03
Conditions
acute painacute inflammation
Beyond the preview
Go deeper on NCT06241742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241742.